Mostrar el registro sencillo del ítem
Ozenoxacin, a new effective and safe topical treatment for impetigo in children and adolescents
dc.contributor.author | Torrelo, Antonio | |
dc.contributor.author | Grimalt Santacana, Ramon | |
dc.contributor.author | Masramon, Xavier | |
dc.contributor.author | Albareda López, Núria | |
dc.contributor.author | Zsolt, Ilonka | |
dc.date.accessioned | 2020-03-01T16:40:39Z | |
dc.date.available | 2020-03-01T16:40:39Z | |
dc.date.issued | 2020 | |
dc.identifier.citation | Torrelo, Antonio; Grimalt, Ramon; Masramon, Xavier [et al.]. Ozenoxacin, a new effective and safe topical treatment for impetigo in children and adolescents. Dermatology, 2020, p. 1-9. Disponible en: <https://www.karger.com/Article/Abstract/504536>. Fecha de acceso: 1 mar. 2020. DOI: 10.1159/000504536. | ca |
dc.identifier.issn | 1018-8665 | ca |
dc.identifier.uri | http://hdl.handle.net/20.500.12328/1473 | |
dc.description.abstract | Background: Ozenoxacin is a topical antibiotic approved in Europe to treat non-bullous impetigo in adults and children aged ≥6 months. This analysis evaluated the efficacy and safety of ozenoxacin in paediatric patients by age group. Methods: Pooled data for patients aged 6 months to <18 years who had participated in a phase I or in two phase III clinical trials of ozenoxacin 1% cream were analysed by age group: 0.5–<2, 2–<6, 6–<12, and 12–<18 years. Results: The combined population comprised 529 patients with non-bullous impetigo treated with ozenoxacin (n = 239), vehicle (n = 201), or retapamulin as internal validation control (n = 89). Studies were well matched for extent and severity of impetigo and therapeutic schedule (twice daily application for 5 days). The clinical success rate after 5 days’ treatment (day 6–7, end of therapy), and microbiological success rates after 3–4 days’ treatment and at the end of therapy, were significantly higher with ozenoxacin than vehicle (p < 0.0001 for all comparisons). Clinical and bacterial eradication rates were higher with ozenoxacin than vehicle in each age group. No safety concerns were identified with ozenoxacin. One (0.3%) of 327 plasma samples exceeded the lower limit of quantification for ozenoxacin, but the low concentration indicated negligible systemic absorption. Conclusion: This combined analysis supports the efficacy and safety of ozenoxacin administered twice daily for 5 days. Ozenoxacin 1% cream is a new option to consider for treatment of non-bullous impetigo in children aged 6 months to <18 years. | ca |
dc.format.extent | 9 | ca |
dc.language.iso | eng | ca |
dc.publisher | Karger | ca |
dc.relation.ispartof | Dermatology | ca |
dc.rights | © 2020 The Author(s). This article is licensed under the Creative Commons AttributionNonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes as well as any distribution of modified material requires written permission. | ca |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.subject.other | Antibiòtics | ca |
dc.subject.other | Infecció | |
dc.subject.other | Pell | |
dc.subject.other | Infants -- Salut i higiene | |
dc.subject.other | Antibiotics | |
dc.subject.other | Infection | |
dc.subject.other | Skin | |
dc.subject.other | Children -- Health and hygiene | |
dc.subject.other | Antibióticos | |
dc.subject.other | Infección | |
dc.subject.other | Piel | |
dc.subject.other | Niños -- Salud e higiene | |
dc.title | Ozenoxacin, a new effective and safe topical treatment for impetigo in children and adolescents | ca |
dc.type | info:eu-repo/semantics/article | ca |
dc.description.version | info:eu-repo/semantics/acceptedVersion | ca |
dc.embargo.terms | cap | ca |
dc.subject.udc | 61 | ca |
dc.identifier.doi | https://dx.doi.org/10.1159/000504536 | ca |
Ficheros en el ítem
Este ítem aparece en la(s) siguiente(s) colección(ones)
-
Ciències de la Salut [745]